TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial

Benzinga Logo Benzinga By Vandana Singh
Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial

Pfizer announced positive Phase 3 BREAKWATER trial data showing its Braftovi combination therapy (with cetuximab and FOLFIRI) demonstrated a 64.4% confirmed objective response rate in BRAF V600E-mutant metastatic colorectal cancer patients, significantly outperforming standard-of-care treatment (39.2%). The drug received accelerated FDA approval in December 2024, with continued approval contingent on verification of clinical benefit.

Insights
MDAIW   positive

The company was featured prominently at a medical conference, received positive quotes from medical professionals, and was recognized on TIME's list of Top HealthTech companies, indicating strong technological and market potential


PFE   positive

Pfizer's Braftovi combination therapy demonstrated clinically meaningful and statistically significant improvements in tumor response rates (64.4% vs 39.2%) compared to standard treatment, with 57.4% of patients achieving responses lasting 6+ months. This strong efficacy data supports the drug's accelerated FDA approval and validates the treatment approach for BRAF V600E-mutant colorectal cancer.